BDC Capital, SR One lead $21 mln Series D round for Thrasos Therapeutics
Thrasos Therapeutics, a Montréal-based biotherapeutics company focused on delivering new treatments for kidney disease, has raised $21 million in a Series D round. BDC Capital and SR One led the financing with the participation of all existing investors, which include Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures. With the deal's closing, BDC Managing Partner Ela Borenstein has joined Thrasos' board of directors. Update: The company said it will use the new investment's proceeds to advance its technology and to position its lead program for the next step in clinical development.
31 March 2015•4 mins read
